The three health agencies were directed to restore those websites as they were Jan. 30 by the end of the day Tuesday.

Federal health agencies have restored several webpages and datasets, following a judge's order to bring back public access to information that had been removed to comply with a presidential executive ...

Filled Syringes: End-to-End Processing Training Course" conference has been added to ResearchAndMarkets.com's offering. This intensive two-day course has been designed to offer a comprehensive, ...

According to Grand View Research, the European and Middle Eastern drug screening markets are projected to grow significantly by 2030, with Europe expected to reach $3.6 billion and the Middle East and ...

The Food and Drug Administration announced it would decide by April 2024 whether chemical hair straightening products sold in the U.S. would be banned from using formaldehyde or ingredients that ...

Typically, funding for treatment can be difficult to come by, with only 600 “orphan” drugs approved for use by the US Food and Drug Administration (FDA). 1 The term’s origin can be found in ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

On Jan. 20, Dr. Robert M. Califf bid farewell to his role as Commissioner of the U.S. Food and Drug Administration in a reflective post on X, formerly Twitter, highlighting the agency’s progress ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

They acknowledge the need for more testing to confirm drug safety and efficacy, but they suggest if these results translate to human patients, ErSO-TFPy could be transformative for ER+ breast ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...